prademagene zamikeracel (Zevaskyn)

From Aaushi
Jump to navigation Jump to search
[1]

Indications

Mechanism of action

  • Zevaskyn consists of a patient's own skin cells that have been genetically modified to contain a functional COL7A1 gene

More general terms

References

  1. ↑ Grasso GM, DiBernardino CL FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa. Healio. April 29, 2025 https://www.healio.com/news/dermatology/20250429/fda-approves-zevaskyn-for-treatment-of-recessive-dystrophic-epidermolysis-bullosa
Retrieved from "https://aaushi.info/w/index.php?title=A59170&oldid=1247194"